Spectrum Pharmaceuticals' Oral Satraplatin

Questions: Discounts, Updates etc.

Price: $3,800.00

Publication Date: 2006-09-06

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

There are no FDA-approved second-line chemotherapy options for hormone refractory prostate cancer, indicating a great unmet need, with a large potential market for an agent such as Spectrum's satraplatin, which could offer key advantages due to its oral administration profile.


Scope

  • Analysis of the regulatory and commercial potential for SPPI's oral satraplatin, the first agent to demonstrate activity in second-line HRPC patients
  • Interviews with 5 prostate cancer specialists regarding trends in the treatment of this disease and the potential role for a second-line HRPC option


    • Report Highlights
    Given its novel oral administration profile and promising efficacy data from a small European trial, if approved, we believe Spectrum Pharmaceuticals' (SPPI) and GPC Biotech's (GPCB) satraplatin could become a widely popular treatment option for second-line hormone-refractory prostate cancer (HRPC) patients.

    Pending results from the recently enrolled Phase III SPARC trial, we anticipate that satraplatin, a third generation platinum agent, could be approved for HRPC as early as mid-2007 and forecast significant revenues for the companies.


    Reasons to Purchase

  • Predict the regulatory and commercial potential for SPPI's oral satraplatin through in-depth analysis based on interviews with leading experts
  • Anticipate likely changes in the future market dynamics for hormone-refractory prostate cancer therapies upon possible launch of oral satraplatin

    • Table of Contents

    Other users found this report page using the following search terms: Spectrum Satraplatin prostate cancer spectrum satraplatin

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.